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Abstract
Recent descriptions of significant heterogeneity in normal stem cells and cancers have altered our understanding of
tumorigenesis, emphasizing the need to understand how single stem cells are subverted to cause tumors. Human
myeloproliferative neoplasms (MPNs) are thought to reflect transformation of a hematopoietic stem cell (HSC) and the
majority harbor an acquired V617F mutation in the JAK2 tyrosine kinase, making them a paradigm for studying the early
stages of tumor establishment and progression. The consequences of activating tyrosine kinase mutations for stem and
progenitor cell behavior are unclear. In this article, we identify a distinct cellular mechanism operative in stem cells. By using
conditional knock-in mice, we show that the HSC defect resulting from expression of heterozygous human JAK2V617F is
both quantitative (reduced HSC numbers) and qualitative (lineage biases and reduced self-renewal per HSC). The defect is
intrinsic to individual HSCs and their progeny are skewed toward proliferation and differentiation as evidenced by single cell
and transplantation assays. Aged JAK2V617F show a more pronounced defect as assessed by transplantation, but mice that
transform reacquire competitive self-renewal ability. Quantitative analysis of HSC-derived clones was used to model the fate
choices of normal and JAK2-mutant HSCs and indicates that JAK2V617F reduces self-renewal of individual HSCs but leaves
progenitor expansion intact. This conclusion is supported by paired daughter cell analyses, which indicate that JAK2-mutant
HSCs more often give rise to two differentiated daughter cells. Together these data suggest that acquisition of JAK2V617F
alone is insufficient for clonal expansion and disease progression and causes eventual HSC exhaustion. Moreover, our results
show that clonal expansion of progenitor cells provides a window in which collaborating mutations can accumulate to drive
disease progression. Characterizing the mechanism(s) of JAK2V617F subclinical clonal expansions and the transition to overt
MPNs will illuminate the earliest stages of tumor establishment and subclone competition, fundamentally shifting the way
we treat and manage cancers.
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Introduction
The hematopoietic system produces multiple types of
specialized blood cells and its lifelong maintenance relies upon
hematopoietic stem cells (HSCs) [1]. One of their most
intriguing characteristics is the execution of balanced fate
choices in order to maintain themselves and to provide the
correct numbers and types of progeny to ensure homeostasis
[2]. When this balance is perturbed, malignancy can result
from the clonal dominance of HSCs that have acquired
differentiation and/or proliferation abnormalities [3]. In order
to understand the balance between self-renewal and differen-
tiation throughout the lifetime of an organism, mathematical
modeling has given seminal insight in epithelial systems where
lineage tracing and defined organ structure have permitted
such analyses [4,5].
Driver mutations within the HSC compartment are associ-
ated with several hematological malignancies. The myeloprolif-
erative neoplasms (MPNs) are of particular interest for several
reasons. Chronic phase MPNs are frequently diagnosed at an
early presymptomatic stage of disease and are associated with
overproduction of morphologically normal mature cells [6,7].
There is no differentiation block and no need for the neoplastic
clone to overcome tissue barriers, hypoxia, or other environ-
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mental hurdles. As a consequence, MPNs provide a window
onto some of the earliest stages of malignancy that are
inaccessible in other cancers. Moreover, they are experimentally
tractable since they readily permit clonal analysis and are
chronic diseases, thereby facilitating the dissection of clonal
evolution [8–10].
In 2005, a single acquired mutation, JAK2V617F, was reported
to be present in most MPN patients [11–14]. Subsequently, several
mouse models have provided important insights into the biological
consequences of mutant JAK2 [15]. More recently, several groups
have developed JAK2V617F knock-in models to study the effect of
physiological levels of JAK2V617F [16–19]. Our model condi-
tionally expresses a single copy of human JAK2V617F under the
control of the mouse Jak2 regulatory elements following pIpC
injection prior to 6 wk of age [19]. These mice (hereafter called
JAK2V617F) develop a phenotype strongly resembling human
JAK2V617F-positive ET with modest increases in platelet and
hemoglobin levels together with transformation to more severe
disease (splenomegaly with erythrocytosis or myelofibrosis) in
,10% of mice. In both competitive and noncompetitive
transplantation experiments, whole bone marrow (BM) from
JAK2V617F mice showed a disadvantage compared to wild-type
(WT) littermate controls [19] reminiscent of oncogene-induced
senescence in other cancers.
Here we have studied the balance of fate choice in highly
purified JAK2V617F HSCs in limiting dose transplantations and
single-cell analyses combined with a mathematical modeling
approach and direct assessment of first division progeny. We
demonstrate that HSCs are reduced in number, exhibit reduced
self-renewal on a per cell basis, and generate progeny that display
increased proliferation and differentiation. Moreover, quantitative
analyses of single HSCs indicate that JAK2V617F reduces HSC
self-renewal whilst leaving intact expansion of early progenitors.
Together our results indicate that JAK2V617F alone compromises
HSC self-renewal and is insufficient to sustain long-term clonal
expansion in the absence of additional mutations.
Results
JAK2V617F Reduces HSC Self-Renewal and Produces
Variable Lineage Outputs
Competitive transplantation studies were performed to investi-
gate the HSC defect observed in JAK2V617F mice. In order to
study the effect of transplanting limiting numbers of HSCs and
investigate potential lineage biases, transplantations were per-
formed using low numbers of donor cells. When transplanted with
105 donor BM cells, mice receiving either WT or JAK2V617F cells
displayed reduced PB chimerism compared to those receiving the
corresponding 106 cell dose (Figure 1A). Importantly, whereas
mice receiving 106 JAK2V617F cells retained a balanced produc-
tion of myeloid and lymphoid lineages, those receiving 105
JAK2V617F cells exhibited marked lineage skewing (Figure 1B) as
determined by the relative production of myeloid and lymphoid
elements by donor and competitor cells.
When transplanted into secondary animals (Figure 1C), BM
cells from primary recipients of 105 WT cells successfully
repopulated secondary recipient mice. BM cells from primary
recipients of 105 JAK2V617F cells also repopulated secondary
recipients, but compared to competitor cells, JAK2V617F cells
produced fewer progeny, with several secondary recipients
displaying no detectable contribution or only low levels of
lymphoid cells. Secondary recipients of JAK2V617F BM cells
again showed lineage skewing, with four of five positive recipients
showing .90% bias toward either the myeloid or lymphoid
lineage (Figure 1D) compared to zero of eight recipients of WT
primary BM. As there are reduced HSC numbers in the
JAK2V617F mice, the observed lineage biases (Figure 1B and
1D) may reflect transplantation of only a few HSCs, thereby
revealing lineage-biased HSCs that have been previously
described [20,21]. Taken together, these results demonstrate that
HSCs from JAK2V617F BM display reduced self-renewal and that
lineage biases emerge when limiting numbers of HSCs are
present.
JAK2V617F E-SLAM HSCs Are Less Numerous and Have a
Reduced Self-Renewal Capacity per HSC
We previously reported reduced numbers of c-Kit+, Sca1+,
lineage negative (KSL) cells in JAK2V617F BM 6 mo following
pIpC injection [19]. While the KSL population contains most
HSCs, only one in 30 can repopulate an irradiated mouse at 2 mo
posttransplantation [22,23], and so we focused these studies on
highly purified CD45+EPCR+CD482CD150+ (E-SLAM) HSCs,
56% of which produce multilineage clones at 4 mo posttransplan-
tation [24]. In JAK2V617F mice, E-SLAM HSC numbers were
reduced 2-fold (p=0.029) compared to WT littermate controls
(Figure 1E and F).
To ascertain whether E-SLAM HSCs from JAK2V617F mice
were less functional than normal controls, 10 donor E-SLAM
HSCs were transplanted alongside competitor BM cells and
secondary transplantations were performed using BM from all the
primary recipients showing even trace amounts of donor-derived
repopulation. For mice receiving WT E-SLAM HSCs, four of five
primary transplant recipients and four of four secondary transplant
recipients displayed long-term contributions by WT test cells at
16–24 wk (Table 1). In contrast, mice receiving JAK2V617F E-
SLAM HSCs gave rise to significantly less long-term repopulation
(p=0.019), with just one of five primary recipients showing a long-
term contribution and three other recipients showing ,1% of
JAK2V617F donor cells at 16–24 wk posttransplantation (Table 1).
Moreover, BM from the primary recipients of JAK2V617F donor
HSCs did not give rise to any long-term contribution in secondary
Author Summary
Recent descriptions of the existence of significant
heterogeneity in normal stem cells and cancers have
altered our understanding of tumorigenesis, emphasizing
the need to understand how single stem cells are
subverted to cause tumours. In this study, we focus on
understanding the stem cell defect that results from a
mutation in the JAK2 tyrosine kinase gene, which is
present in the majority of patients with myeloproliferative
neoplasms (MPNs), a group of clonal bone marrow
diseases that are characterised by the overproduction of
mature blood cells and increased frequency of leukaemia
development. By using single-cell assays and mathemat-
ical modeling, followed by the individual assessment of
daughter cells from single HSCs, we identify a distinct
cellular mechanism that differentially affects stem cell and
progenitor cell expansion. Specifically, we show that this
single point mutation can negatively affect HSCs while
leaving progenitor cell expansion intact. Characterising
the mechanisms that link JAK2 mutations with clonal
expansions that eventually lead to development of MPNs
will inform our understanding of the earliest stages of
tumour establishment and of the competition between
subclones of proliferating progenitor/stem cells. These
findings have direct relevance to all cancers of a
suspected stem cell origin.
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recipients (Table 1). JAK2V617F E-SLAM HSCs showed no
difference in their ability to home to the bone marrow within
the first 36 h posttransplantation compared to E-SLAM HSCs
from WT littermate controls (Figure S1D and Methods S1).
Collectively, these data demonstrate that E-SLAM HSC numbers
are reduced in JAK2V617F animals and are functionally compro-
mised in long-term serial transplantation assays.
JAK2V617F E-SLAM HSCs Have a Survival Advantage
In Vitro and Generate Larger, More Differentiated Clones
To study the stem cell defect in individual HSCs, we used a
single-cell in vitro culture system previously reported to maintain
numbers of long-term repopulating cells [20,25]. Single E-SLAM
HSCs (n=720), obtained from JAK2V617F mice or WT littermate
controls, were assessed for survival, early kinetics of cell division,
Figure 1. JAK2V617F induces a loss of self-renewal activity and HSC numbers and leads to a lineage bias when limited HSCs are
transplanted. (A) Relative chimerism following transplantation of 106 or 105 JAK2V617F or wild type (WT) whole bone marrow (BM) 6–10 months
post-pIpC along with 56105 whole BM competitor cells into eight recipient mice. Average chimerism was lower in mice receiving JAK2V617F cells
(p=0.03). (B) The relative myeloid (purple) versus lymphoid (green) contribution in each of the recipient animals were determined by calculating a
ratio between the contribution to the myeloid compartment [Donor GM/(Donor GM+Competitor GM)] and lymphoid compartment [Donor BT/
(Donor BT+Competitor BT)]. (C) Relative chimerism in primary peripheral blood (PB) (white bars) in the eight animals receiving 105 cells compared to
levels of PB chimerism in the 16 secondary recipients (two per primary animal, grey bars) in two independent transplantation experiments. An ‘‘X’’
represents a recipient that showed less than 1% chimerism at 24 wk posttransplantation, and a ‘ represents a recipient that only had contribution to
the lymphoid lineages. (D) The relative myeloid (purple) versus lymphoid (green) contribution in each of the secondary recipient animals were
determined by calculating a ratio between the contribution to the myeloid and lymphoid compartments as in Figure 1B. (E) The FACS isolation
strategy for CD45+/EPCR+/CD482/CD150+ (E-SLAM) cells. The panels are gated on viable white blood cells and show E-SLAM gates for WT (top) and
JAK2V617F (bottom). (F) The frequency of E-SLAM HSCs per 105 viable bone marrow (BM) cells in four WT and four JAK2V617F mice 6–10 mo following
pIpC injection from four independent experiments. The frequency is reduced in JAK2V617F animals (p=0.0288).
doi:10.1371/journal.pbio.1001576.g001
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proliferation, and differentiation state (Figure 2). Compared to
WT E-SLAM HSCs, the number of wells giving rise to a 10-d
clone from JAK2V617F E-SLAM HSCs was increased by
approximately 50% (p=0.05, Figure 2B) and the average clone
size was also increased (p=0.016, Figure 2C). Clones derived from
JAK2V617F HSCs contained more differentiated cells (Lin+)
(p=0.006, Figure 2D), but did not show a significant increase in
KSL cells (Figure 2E). Compared to WT equivalents, JAK2V617F
E-SLAM HSCs displayed similar cell cycle kinetics during their
first two rounds of cell division (Figure S1A) and gave rise to
similar levels of apoptotic cells after 10 d of culture (Figure S1B).
These results demonstrate that JAK2V617F E-SLAM HSCs are
more clonogenic and give rise to more progeny expressing
differentiation markers under conditions that normally maintain
HSC numbers.
To investigate the differentiation potential of JAK2V617F HSCs,
individual pools of 100–400 E-SLAM HSCs were cultured in SCF
and IL-11 and assessed at 14 d for expression of several
differentiation markers. Compared to WT equivalents, JAK2V617F
E-SLAM HSC-derived clones contained a higher percentage of
CD41+ cells (p=0.003), a lower percentage of Ly6g+ and/or
Mac1+ cells (p=0.008), and similar percentages of CD71+ cells
(Figure 2F–H). When absolute numbers of cell types were taken
into account, the increase in CD41+ cells was even more
pronounced (Figure 2I). The increased proportion and absolute
number of CD41+ cells are consistent with a bias toward
megakaryocytic differentiation, which was also observed in vivo
[19]. However, the SCF and IL-11 culture conditions are
specifically selected to maintain stem and progenitor cells and do
not optimally support the production of more mature blood cells.
Therefore, in order to further test the differentiation potential of
JAK2V617F E-SLAM HSCs, we undertook a series of functional
assays.
JAK2V617F E-SLAM HSCs Generate More Short-Term
Progenitors But Fewer Cells with Durable Self-Renewal
Activity
The results described above show that JAK2V617F E-SLAM
HSCs make larger, more differentiated clones compared to WT
E-SLAM HSCs, but did not allow us to assess the production of
functional progenitors. We therefore performed short-term
progenitor assays and long-term transplantation assays on the
progeny of cultured E-SLAM HSCs (Figure 3A). Individual pools
each containing 100–400 E-SLAM HSCs were cultured for 10 d,
and the progeny were assessed by CFC assays or transplanted at
different doses into irradiated recipients. In CFC assays,
JAK2V617F cells gave rise to significantly more BFU-E
(p=0.007) and CFU-GM (p=0.009), but displayed no increase
in the number of CFU-GEMM (Figure 3B). The CFC culture
conditions do not detect lymphoid progenitors, and so these
results do not exclude expansion of lymphoid-committed
progenitors.
In transplantation experiments, the 10-d progeny of 40, 33, or 4
HSC starting equivalents were injected into a total of 38 irradiated
recipient mice to assess self-renewal during the in vitro culture.
While cultures derived from WT E-SLAM HSCs repopulated
most recipients using 40 (5/6) or 33 (4/5) E-SLAM starting
equivalents, those derived from JAK2V617F E-SLAM HSCs
contained substantially fewer cells capable of long-term repopu-
lation (1/6 and 2/5 recipients repopulated, respectively). Overall,
JAK2V617F E-SLAM HSCs retained 5–6-fold fewer HSCs over
10 d compared to WT equivalents (p=0.005, Figure 3C). These
data demonstrate that JAK2V617F E-SLAM HSCs underwent
markedly fewer HSC self-renewal divisions, but produced similar
numbers of primitive progenitors (CFU-GEMM) and generated
significantly more erythroid and granulocyte/macrophage (GM)
progenitors.
JAK2V617F Mice Progress to More Severe Disease, But in
Those That Do Not, E-SLAM HSCs Are Not Expanded, Are
Less Proliferative, and Lack Increased Clonogenicity In
Vitro
To understand the normal aging of HSCs in the absence of high
replicative stress (e.g., transplantation in vivo or high doses of
hematopoietic cytokines in vitro), we generated a cohort of aged
WT and JAK2V617F mice. Six of 80 JAK2V617F mice (but none of
92 littermate controls) were sacrificed, at a median of 9 mo post-
pIpC injection, as a consequence of transformation to diseases
resembling PV or MF. Together with mice from a smaller cohort
on a mixed 129Sv/C57Bl6/J background [19], 10 mice developed
either a PV phenotype or an MF phenotype. Transformation to
PV was accompanied by marked erythrocytosis, splenomegaly,
and low platelets, whereas MF transformation was accompanied
by BM fibrosis and splenomegaly together with anemia and
variable white cell and platelet counts (Table S1).
Normally HSCs undergo several qualitative and quantitative
changes with increasing age including a variably expanded
phenotypically defined HSC pool, delayed proliferative responses
in vitro, and reduced functional capacity in vivo as measured by
transplantation of purified HSCs [26–28]. We therefore analyzed
BM from JAK2V617F mice and WT littermate controls that were
18–24 mo after pIpC injection (hereafter called old mice). In WT
mice, the E-SLAM HSC compartment was ,2-fold larger in old
Table 1. Primary and secondary transplantation of 10 highly
purified JAK2V617F or wild type E-SLAM HSCs.
Dose Wild type JAK2
V617F
Mouse % Chimerism Mouse % Chimerism
Primary (10
HSCs)
A 15 F 2
B 10 G 0*
C 47 H 0*
D 38 I 0*
E 0 J 0
Secondary
(66106)
From A 3, 7 From F 0, 0
From B 3, 2 From G 0, 0
From C 80, 28 From H 0, 0
From D 30, 36 From I 0, 0
Donor bone marrow was harvested and E-SLAM HSCs isolated as shown in
Figure 1E. Ten E-SLAM HSCs from JAK2V617F mice 6–10 mo following pIpC
injection or their wild-type littermate controls were transplanted into each of
five irradiated recipients alongside 200,000 competitor cells. The numbers of
successful transplantations and their respective chimerism levels are shown
above for both primary (10 E-SLAM HSCs) and secondary (66106 bone marrow
cells from the primary animal) transplantations. A successful transplantation
was defined as those showing .1% donor peripheral blood chimerism (out of
donor+competitor) at 16–24 wk and at least 0.5% peripheral blood chimerism
within each lineage (GM, B, and T) at some point over the 16-wk period. For
each primary mouse, two secondary transplantations were performed and the
original parent is indicated. Mice showing trace amounts of repopulation (,1%)
are marked with an asterisk (*).
doi:10.1371/journal.pbio.1001576.t001
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mice compared to younger mice (compare Figure 4A to Figure 1F).
However, the same comparison in JAK2V617F mice shows that the
E-SLAM HSC compartment was not expanded in old mice. As a
consequence, there was a 3-fold reduction (p=0.002) in the
frequency of E-SLAM HSCs in old JAK2V617F mice compared to
their WT littermate controls.
To investigate whether or not the remaining JAK2V617F HSCs
aged in the same way as WT HSCs, we cultured 317 single E-
SLAM HSCs. Both WT and JAK2V617F E-SLAM HSCs from old
mice displayed decreased cell cycle entry at 48 h compared to
their younger counterparts (compare Figure 4B to Figure S1C).
This effect was more marked in old JAK2V617F E-SLAM HSCs,
which exhibited significantly delayed entry into the first cell cycle
relative to old WT E-SLAM HSCs (p=0.039, Figure 4B). In
contrast to E-SLAM HSCs derived from younger mice, old
JAK2V617F E-SLAM HSCs did not show an increase in cloning
efficiency (compare Figure 4C with Figure 2B) or produce
significantly more cells per clone compared to WT equivalents
(compare Figure 4D with Figure 2C). However, like their younger
counterparts, old JAK2V617F E-SLAM HSCs generated more
differentiated cells (Figure 4E) and similar numbers of stem/
progenitor cells per clone (Figure 4F) compared to WT littermate
controls. Moreover, freshly isolated E-SLAM HSCs from old
JAK2V617F mice accumulated more DNA damage as determined
by a greater number of c-H2AX foci compared to WT equivalents
(Figure S1G).
We next undertook competitive transplantation experiments to
assess the relative repopulating ability of old JAK2V617F BM and
found that it was significantly reduced (p,0.01) at 4 mo
posttransplantation (Figure 4G). Importantly, when we performed
competitive transplantation experiments on the BM from
JAK2V617F mice that had transformed, this reduction in compet-
itive repopulating ability was not present (Figure 4G), indicating
that HSC activity is recovered in transformed mice. Moreover, in
one animal, the numbers of E-SLAM HSCs was increased relative
to an age-matched WT control (Figure S1E), consistent with the
concept that transformation to PV is accompanied by recovery of
HSC numbers.
Together, our data therefore demonstrate that in younger mice,
JAK2V617F reduces HSC numbers and mutant HSCs produce
Figure 2. JAK2V617F HSCs have an initial survival advantage and make larger, more differentiated clones. (A) Schematic for single cell in
vitro cultures. Individual CD45+/EPCR+/CD482/CD150+ (E-SLAM) cells, obtained from mice 6–10 mo following pIpC injection, were sorted into single
wells and cultured for 10 d in 300 ng/mL SCF and 20 ng/mL IL-11 in four independent experiments. (B) The average cloning efficiency was higher
(p=0.05) for JAK2V617F (red bars) versus wild type (blue bars) cells and was measured by counting the number of sorted events that give rise to a
colony after 10 d. (C) The average number of cells per clone was higher (p=0.016) in JAK2V617F cells. JAK2V617F HSCs give rise to more differentiated
cells (p= 0.006) as measured by the expression of one or more of a panel of lineage markers (CD5, Mac1, CD19, B220, Ly6g, 7-4, or Ter119, panel D)
and expression of c-Kit and Sca1 as a surrogate for stem/progenitor cell number (E). Fourteen-day cultures of 100–400 E-SLAM HSCs in SCF+IL-11
followed by flow cytometric analysis of the cells show that, by proportion, JAK2V617F HSCs make more CD41+ (p=0.003, F), and less Ly6g/Mac1+ cells
(p=0.008, G) than wild-type controls in three independent experiments. The proportion of CD71+ cells generated was not changed (H). (I) The
absolute numbers of Ly6g/Mac1+ and CD71+ cells generated were not different, but the number of CD41+ cells produced was increased
approximately 2-fold (p=0.023).
doi:10.1371/journal.pbio.1001576.g002
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more progeny than WT equivalents. By contrast, in old mice
JAK2V617F is not associated with the usual expansion of the HSC
compartment, and unlike their younger counterparts, mutant
HSCs are no longer more productive than WT equivalents,
however they recover their HSC activity in animals that transform
to more severe disease.
Quantitative Analysis of Single HSC-Derived Clones
Shows That JAK2V617F Does Not Compromise
Progenitor Cell Self-Renewal
To understand the self-renewal and differentiation capacity of
individual HSCs and their progeny, we combined a quantitative
analysis of short-term clone size data with a more detailed analysis
of the colony size and cell type composition after 10 d in culture
using the data presented in Figure 2. Consistent with previous
reports [25,29], HSCs exposed to SCF and IL-11 rarely entered
the cell cycle before 24 h and had an average time to first division
of approximately 40 h (Figure S1A). After this initial lag, HSC-
derived clones underwent steady exponential expansion at a
constant rate for the first 4–5 rounds of division, suggesting that
few cells, if any, exited the cell cycle (Figure 5A). Clones then
underwent a substantial increase in their average cell division rate.
At the end of the time course, the average clone size increased less
rapidly, consistent with cells committing to terminal differentiation
(Model S1 and Figure S2).
To gain further insight into the scale of the lineage hierarchy,
and fate behavior of HSCs and their differentiating progeny, we
developed a biophysical modeling scheme to address the range of
experimental data. On the assumption that HSCs constitute an
equipotent pool, we supposed that HSCs and their differentiating
progeny are organized in a unidirectional hierarchy. The KSL
fraction of mouse bone marrow cell cultures has been shown
previously to contain the vast majority of HSCs together with a
larger number of progenitor cells [30]. Therefore, we defined KSL
as stem and early progenitor cells, Lin2/non-KSL as progenitor
cells further down the hierarchy, and Lin+ as cells that have
differentiated (Figure 5B).
Secondly, it was assumed that HSC self-renewal occurs within
the culture system. This is supported by transplantation assays that
demonstrate the culture conditions used here maintain the input
Figure 3. Cultured JAK2V617F E-SLAM HSCs produce more short-term progenitors, but lack long-term reconstitution ability. (A) Cells
derived from cultures of 100–400 E-SLAM HSCs were harvested after 10 d of culture in SCF and IL-11 and then placed in a colony-forming cell (CFC)
assay to determine the number and type of progenitor cells made or were transplanted into irradiated recipients to determine whether or not long-
term reconstituting ability was retained. (B) Following 10–14 d of culture in the CFC assay, colonies were scored and enumerated. Colonies were
scored as either Erythroid (E), Granulocyte/Macrophage (GM), or Granulocyte/Macrophage/Erythroid/Megakaryocyte (GEMM) progenitors and are
represented by bar graphs showing the mean +/– SEM of four to six biological replicates from four independent experiments. A greater number of
GM (p= 0.009) and E (p=0.007) were observed in CFCs derived from JAK2V617F cultures. (C) Varying doses (40, 33, 4) of HSC starting equivalents (the
proportion of the total culture that would have been made by that input number of HSCs) were transplanted to determine the frequency of cells that
had retained long-term reconstituting ability in two independent experiments. This is followed by a limiting dilution analysis that estimates the
frequency of HSCs retained in the culture. Cultures of JAK2V617F HSCs make 5–6-fold fewer HSCs in culture compared to WT littermate controls
(p=0.00469). * HSC dose is defined as the number of starting equivalents that were transplanted. In the case of ‘‘40,’’ this is representative of
transplanting all of the cells that would be generated from a 10-d culture of 40 HSCs. ** A mouse was considered to be positive if it had .1% donor
chimerism at 16–24 weeks and represented at least 0.5% of each lineage (GM, B, and T) at some point over the 16-wk period.
doi:10.1371/journal.pbio.1001576.g003
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number of stem cells, meaning that cells at the apex of the hierar-
chy form a self-renewing population [25]. Moreover, transplan-
tation efficiency of single HSC-derived clones (assessed as a binary
outcome in primary recipient mice) declines with time in culture
[25,29], suggesting that the balance between HSC differentiation
and self-renewal is achieved at the population level, but not at the
level of individual cells (i.e., HSCs follow a balanced stochastic cell
fate, leading to neutral drift-type dynamics of the clones).
Thirdly, it was supposed that, as HSCs progressively differen-
tiate, they move through a cascade of intermediate tiers, which
retain a degree of self-renewal potential before leaving the KSL
compartment. On the basis of the colony expansion over the 10-d
time course and the average number of KSL cells produced at 10 d
postplating, we concluded that approximately seven such distinct
differentiation tiers exist in the KSL compartment (Model S1).
Figure 5C shows the cumulative clone sizes derived from the
WT data described in Figure 2. Adjusting the division and loss
rates to fit the colony growth curve over the 10-d time course
(Figure 5A), we find that the model provides a good fit to the
cumulative clone size distributions of the KSL, Lin2/non-KSL,
Figure 4. E-SLAM HSCs do not expand in old JAK2V617F knock-in mice and show reduced functional ability as well as a delayed
entry into the cell cycle. (A) E-SLAM HSCs were increased in frequency in wild type (,2-fold, see Figure 1E) but not JAK2V617F marrow in 18–24-mo-
old mice (n= 10) compared to 6–10-mo-old mice resulting in a 3-fold overall reduction in E-SLAM HSCs compared to wild-type (p=0.002) in three
independent experiments. (B) Individual HSCs were cultured and cell counts were recorded on day 1 and day 2 to determine whether or not they had
undergone a division in three independent experiments. At day 2, significantly fewer (p= 0.039) old JAK2V617F HSCs had divided. The cloning
efficiency (C), number of cells per clone (D), and number of KSL cells per clone (F) were not different, but the JAK2V617F cells still produced more
differentiated cell types after 10 d of culture (p= 0.039, E). (G) Competitive transplantation of whole bone marrow from old JAK2V617F mice,
transformed JAK2V617F mice, and their respective WT littermate controls. Relative chimerism is calculated by measuring donor chimerism as a
percentage of donor+competitor chimerism and normalized to the average of the WT contribution (set to 1). The old JAK2V617F BM displays reduced
chimerism (p,0.01), whereas transformed JAK2V617F mice that have undergone transformation reacquire their self-renewal capacity.
doi:10.1371/journal.pbio.1001576.g004
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Figure 5. JAK2V617F E-SLAM HSCs, but not progenitors, are tilted toward differentiation. (A) The average clone size data for WT and
JAK2V617F E-SLAM HSCs are approximately exponential over the 10-d time course. At early times, the data for both cell types show that the expansion
is geometrical, with individual clones expanding from one to two to four to eight cells. After several rounds of division, the average cell division rate
appears to accelerate significantly, while nearer to 10 d, there is a deceleration most likely due to cells exiting cycle. The dashed line shows what
exponential growth would look like with the average doubling rate of the first 4–5 rounds of division (1.06 for WT and 1.26 for JAK2V617F), and the
solid line represents the model fit to the actual data points for WT (left) and JAK2V617F (right) clones (for details, see Model S1). Note that, in both
cases, division rates must increase to accommodate the expansion measured at day 10. (B) A schematic of the model dynamics. In the WT situation,
cells move through a differentiation hierarchy with HSCs at the apex. In the model, the division of an HSC leads to symmetric duplication or
differentiation with equal probability (i.e., x = 50%). Cells at the first generation of the differentiating hierarchy then have a capacity to duplicate or
symmetrically differentiate into cells in the next tier of the hierarchy, and the model can be tuned to allow x to vary throughout (see Model S1 for
further details). (C) The cumulative size distribution of clones 10 d postplating by cell type in WT clones—i.e., the KSL data point at (4k, 40%) in the
WT graph—shows that 40% of the colonies have at least 4,000 KSL cells, etc. (D) Comparison of the balanced self-renewal model (i.e., with x = 50%
within the entire stem and progenitor cell compartments) with parameters inferred from a fit to the colony growth curve (A) and cell type averages at
10 d postplating, against the experimental data (points) taken from (C) and (E). The vertical lines (color coded by cell type) represent the expected
range of fluctuations of the cumulative size distribution due to small number statistics, and are inferred from the average and first standard deviation
of the results of the model simulation with 1,000 trials each with a cohort of 68 (WT) and 125 (JAK2V617F) colonies, consistent with that used in
experiment (for further details and model parameters, see Model S1). (E) The same data set as in 5C and 5D, but with model predictions when just
40% of the progenitor cell progeny (x = 40% for the non-HSCs tiers) remain at the same tier of the hierarchy. Note the departure of the line for the KSL
population, which reflects the premature escape of cells from the top of the hierarchy. (F) The cumulative size distribution of colonies 10 d
postplating by cell type in JAK2V617F clones. (G) The balanced self-renewal model (i.e., with x = 50% within the entire non-HSC progenitor
compartment) overlaid onto the data from JAK2V617F clones with solid lines displaying the predictions of the model. The departure of the model from
the observed data is visible in the total viable cells where the model predicts more viable cells in order to produce the observed number of KSL and
Lin-/non-KSL cells. (H) Here the lines shown represent a model where HSC self-renewal has been set to 0 implying that every division of an HSC will
result in differentiation to the next tier, but progenitor self-renewal remains intact within the rest of the non-HSC progenitor cell compartments. Note
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and total cell population at 10 d postplating (Figure 5C,D, and
Figures S3 and S4) if we assume that all proliferative cells undergo
perfect (balanced) self-renewal. To assess the quality of the fit, we
have used the numerical simulation to estimate the expected range
of errors due to small colony number statistics (for details, see
Model S1). The robustness of the fit is further reinforced by the
relatively poor agreement between the model and experiment even
when progenitor cells show only a 10% tilt towards differentiation
(compare Figure 5D to Figure 5E). Even with this small bias, the
predicted number of KSL cells is shifted to values significantly
smaller than that observed in experiment (blue line, Figure 5E).
Importantly, these results indicate that balanced self-renewal
occurs within multiple tiers of early progenitor cells.
Our transplant data show that long-term self-renewal activity of
JAK2V617F HSCs is compromised, and our in vitro studies indicate
that JAK2V617F HSCs generate more progenitor cells over the 10-
d time course (Figure 2B–D and Figure 3B). We therefore
postulated that the self-renewal defect might affect HSCs but not
progenitors. Direct comparison of the WT and JAK2V617F colony
size data (Figure S3) showed that, although the distributions are
significantly tilted toward differentiation, the colonies show the
same characteristic dispersion in size and composition. To further
explore this possibility, clonal composition data obtained using
JAK2V617F E-SLAM HSCs were compared with model simula-
tions in which HSC or progenitor self-renewal was altered. In
common with the clones derived from WT HSCs, those created
from JAK2V617F HSCs displayed approximately exponential
growth (Figure 5A), had a similar delay prior to their first division
(Figure S1A), and showed very poor agreement with simulations
where progenitor cell self-renewal was abolished or even reduced
by only 10% (unpublished data). Furthermore, when the model
included perfectly balanced self-renewal (i.e., 50%) of both HSCs
and progenitors, the observed fit with data from the JAK2V617F
clones was relatively poor, resulting in expected clone sizes much
larger than actually observed (Figure 5G and Model S1).
By contrast, when HSCs were endowed with no self-renewal
potential (i.e., all HSCs undergo differentiation) but progenitor cell
self-renewal remained intact, a good agreement of the model with
the experimental data could be obtained (Figure 5H and Model
S1). Moreover, satisfactory fits of the model to the data were also
found when HSC self-renewal was set at 10% or 20% (Figure S5
and unpublished data). We also undertook the same iterative
analysis using old HSCs from WT and JAK2V617F mice, making
allowance for their delayed cell cycle entry. The observed cell type
distributions agreed well with model predictions for both WT and
JAK2V617F clones (Figure S6 and Model S1).
Importantly, this model is not capable of providing a precise
prediction of the degree of bias. Nevertheless, taken together, our
results suggest that, following the acquisition of the JAK2 mutation,
the self-renewal potential of HSCs is diminished while the behavior
of their more differentiated progeny is left largely unchanged.
Paired Daughter Cell Analysis Reveals a Direct Effect by
JAK2V617F on HSCs
To challenge the prediction that JAK2V617F alters the balance
between proliferation and differentiation at the apex of the stem
cell hierarchy, we undertook a paired daughter cell analysis to
assess the fate outcome of the first division of HSCs from
JAK2V617F mice and their littermate controls. To this end, the
progeny of the first cell division of input HSCs were split into
individual cultures and, after 10 d, assessed by flow cytometry (see
Methods S1 for splitting procedure). We elected to use the average
fraction of KSL cells from the WT as a benchmark for self-
renewal, since HSCs have been shown to undergo approximate
balanced self-renewal under these culture conditions (previous
transplantation data [20,25] and Figure 3). We estimated the
outcome of the first division based on whether progeny of the
doublets were individually above or below the average (see
Methods S1 for further detail). The frequency (Figure 6A) and
absolute number (Figure 6B) of KSL cells per daughter cell were
measured for each doublet to assess the degree of symmetry
between daughters. Applying this procedure, the data indicate that
the divisions of WT HSCs lead to all three possible fate outcomes
in roughly equal proportion (Figure 6C). In particular, divisions
leading to symmetric self-renewal appear to be in balance with
those leading to symmetric differentiation, as expected. Moreover,
when referred to their average KSL content, the data from the
JAK2V617F HSCs also showed approximate balance (unpublished
data), consistent with balanced self-renewal remaining intact at the
lower progenitor tiers, despite compromised HSC self-renewal.
Analysis of the fate of JAK2V617F doublets using the average
fraction of KSL cells from the WT as the benchmark demon-
strated a significant increase in symmetric differentiation divisions
(p=0.04), mainly at the expense of fewer asymmetric cell divisions
(p=0.01). These data suggest that JAK2V617F directly affects
HSC fate choice in vitro, with consequent loss of HSCs.
Discussion
Establishing and maintaining a clone is a fundamental property
of cancers, and it is therefore critical to understand the effect of
individual oncogenes on the balance between self-renewal and
differentiation. To our knowledge, this study represents the first to
isolate single stem cells and study their individual response(s) to a
driver mutation associated with a human malignancy. Our results
show that JAK2V617F alters HSC fate choices, skewing toward
differentiation and proliferation, and quantitative analysis of
individual clones predicts that JAK2V617F exclusively affects
the self-renewal ability of individual HSCs but leaves intact the
expansion capacity of progenitors. This represents a distinct
cellular action for JAK2V617F in stem cells compared to
progenitor cells, although our in vitro studies do not necessarily
imply the same behaviour in vivo and do not address the potential
role of the hematopoietic microenvironment. Importantly, the
negative effect of JAK2V617F on HSC self-renewal suggests the
need for additional mutations to drive clonal expansion consistent
with our results showing recovery of HSC self-renewal in
transformed animals (Figure 6D).
JAK2V617F mice express a single copy of human JAK2V617F
and develop a phenotype that is highly reminiscent of patients with
ET. As in JAK2V617F mice, splenomegaly is rare in chronic phase
ET patients and the JAK2 mutation is associated with a mild but
significant increase in hemoglobin that still lies within the normal
range [31–33]. The modest increase in platelet counts is also
consistent with patient data where the median platelet count is 846
[33], and JAK2V617F-positive individuals with platelet counts in
the 400s can readily be identified [34]. Furthermore it is well
recognized that a small minority of ET patients transform to PV or
MF, consistent with the 10% transformation rate observed in
JAK2V617F mice.
the strong overlap of the model with the data points from the JAK2V617F clones. In panels C–H, the total size colony is represented by black, Lin-/non-
KSL cells are beige, and KSL cells are blue.
doi:10.1371/journal.pbio.1001576.g005
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It is informative to compare the phenotype of the JAK2V617F
mice described here, which express heterozygous human
JAK2V617F, with that of other JAK2V617F knock-in models
[16–18]. Heterozygosity of JAK2V617F is associated with varying
degrees of erythrocytosis, an observation that may reflect different
gene-targeting strategies or the use of human instead of mouse
JAK2V617F (reviewed in Li et al. 2011 [15]). When the stem and
progenitor cell compartment was studied, one group described
increased numbers of stem/progenitor cells (KSL) in Jak2-mutant
compared to WT mice [16], and another reported no difference in
either KSL or CD482/CD150+KSL frequency or function at
16 wk posttransplantation [17], though a later report has now
described a competitive advantage over WT cells that can be
observed beyond 1 y transplantation [35]. It is unclear why these
models expressing mouse JAK2V617F differ from each other in
the timing and magnitude of their effect on HSCs [15,36].
Importantly, the serial transplantations performed in the Mullally
study [17], which follow donor cells through two rounds of
transplantation, take place over a total of 3–4 mo compared to the
18 mo that our JAK2V617F cells were followed. Moreover, our
Figure 6. JAK2V617F alters the balance of HSC fate choices. (A) A paired daughter cell analysis of WT and JAK2V617F HSCs shows both
daughters differentiate more often from JAK2V617F parent HSCs than from WT HSCs as shown by measuring the percentage of KSL cells remaining
after 10 d. Each paired daughter set is connected by a line and the pairs are categorized into symmetric SR (both daughters above the WT average
%KSL), asymmetric division (one daughter above and one below the average %KSL), and symmetric differentiation (both daughters below the
average %KSL). Note the relative increase in symmetric differentiation at the expense of asymmetric divisions. (B) The same paired daughter pairs are
displayed here by the absolute number of KSL cells produced. Here it is clear that some of the JAK2V617F pairs produce very few KSL cells (less than
100 per clone in some of the asymmetric divisions and symmetric differentiation divisions compared to WT HSCs, which are all above 100 KSL cells).
(C) The pie graph on the left represents the outcome from 78 WT paired daughters (39 pairs), and the pie on the left represents the outcome from 76
mutant paired daughters (38 pairs). (D) Normally, HSCs will execute one of several programs in concert with the other HSCs to provide the requisite
numbers of stem cells, progenitors, and differentiated cells for the organism. JAK2V617F disturbs this balance and increases the likelihood of
differentiation. As HSCs with the V617F mutation age, they have both an increased chance of fully exhausting as well as an increased chance of
progressing to a more severe disease state, likely due to the acquisition of additional genetic or epigenetic perturbations.
doi:10.1371/journal.pbio.1001576.g006
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experiments use both purified HSC fractions and secondary
transplantation analyses to fully characterize stem cell function,
and unlike other knock-in models [16–18], the function of JAK2
mutant HSCs is compared to WT littermate controls.
Given the phenotypic differences between the various knock-in
models, the conclusions of our article relate specifically to the
JAK2V617F model studied here, which, as described above,
recapitulates many features of human ET. It must also be
remembered that HSCs from all of these knock-in models express
JAK2V617F at the same time and do not model the acquisition, in
a single cell, of a mutation that attains a clonal advantage and
drives disease in the presences of nonmutant HSCs. This
underscores the usefulness of performing competitive transplanta-
tion experiments using purified HSCs (Table 1), where JAK2
mutant HSCs are placed into a wild-type environment alongside
wild-type cells.
The stem cell defect that we observe in JAK2V617F mice is also
consistent with previous studies of normal individuals and MPN
patients. A recent study of nearly 4,000 individuals attending
outpatient clinics reported a nearly 1% incidence of JAK2V617F,
suggesting that it is insufficient to drive disease [37]. Furthermore,
within MPN patients, allele burden is higher in granulocytes
compared to CD34+ cells [38], only a minority of CD34+CD382
stem and progenitor cells bear the JAK2V617F mutation in many
individuals with ET or PV [39–41], and CD34+ cells expressing
the mutation failed to out-compete normal cells in transplantation
experiments using immunodeficient mice [40,42]. Moreover,
JAK2V617F allele burden is stable over many years in patients
with chronic phase ET or PV [43], and the neoplastic clone failed
to expand following accidental allogeneic transplantation of donor
JAK2V617F mutant cells [44].
Our observations agree with data from patient samples carrying
the BCR-ABL mutation. In patients, both JAK2V617F and BCR-
ABL are associated with MPNs, are acquired early, and result in
expansion of lineage-committed progenitors with overproduction
of mature cells. HSCs expressing BCR-ABL are underrepresented
in the most primitive cell compartment [45] and display reduced
in vitro self-renewal in long-term cultures [46,47], reduced self-
renewal in transplantation experiments in immunodeficient
animals [48], and increased genomic instability [49,50]. More-
over, recent knock-in models of BCR-ABL [51] and FLT3-ITD
[52] (a third tyrosine kinase associated with myeloid malignancies)
have both been shown to compromise HSC self-renewal in
transplantation experiments.
The observation that the JAK2V617F mutation impairs HSC
self-renewal needs to be reconciled with its prevalence in MPNs. It
is important to note that the defect we observe is relatively subtle
and requires serial transplantation assays to be revealed; acquisi-
tion of JAK2V617F would therefore not be predicted to result in
clonal extinction during the lifespan of a patient. Our results
accord with loss-of-function studies using several nontyrosine
kinase tumour suppressors (e.g., Rb [53], PTEN [54], p16 [55],
and p21 [56]), each of which has been associated with loss of HSC
self-renewal, and it has been postulated that tissue stem cells might
use a self-renewal disadvantage as barrier to tumor transformation
[57]. This concept suggests that subsequent clonal expansion
requires a selective advantage, which could reflect acquisition of
new genetic lesions, but could also result from an environmental
change that selects for mutant HSCs that were previously
disfavored [57]. In some MPN patients, mutations in other genes
(e.g., TET2) have been shown to precede acquisition of
JAK2V617F [58,59] and may counteract its negative effects on
HSC function. Consistent with this concept, TET inactivation
results in HSC expansion [58] and the HSC compartment is
expanded in some PV patients, in whom the majority of the HSCs
do not bear the JAK2 mutation [39]. Such a ‘‘pre-JAK2’’ phase is
also consistent with the observation that AML, arising from a
JAK2-mutant chronic phase MPN, frequently lacks the JAK2
mutation [43,60]. Furthermore CD34+ cells from patients bearing
both TET2 and JAK2 mutations demonstrated robust and
increasing chimerism in xenotransplantation experiments, whereas
those with a JAK2 mutation alone declined over time [58].
JAK2V617F may play a causal role in acquisition of additional
mutations since it is associated with increased DNA damage
[19,61], reduced apoptosis of DNA-damaged cells [62], and as we
show in this article, increased proliferation of early progenitors.
It will be important to understand how JAK2V617F cooperates
with the increasing number of other lesions being identified in
chronic phase MPNs, notably Idh1/2, Tet2, Asxl1, and Dnmt3a
(reviewed in [63]). Further characterization of the mechanisms
whereby JAK2V617F is associated with subclinical clonal expan-
sions and overt MPNs will illuminate the earliest stages of tumor
establishment and subclone competition.
Material and Methods
Mice
JAK2V617F mice were generated as described previously [19]
and backcrossed onto a C57Bl/6 background for 10 genera-
tions. Mice in these studies were between 6 mo and 24 mo post-
pIpC injection. The PCR to detect the proportion of recom-
bined allele in HSCs from transformed and recipient animals
was performed as described previously (Figure S1F) [19]. All
mice were kept in specified pathogen-free conditions, and all
procedures performed according to the United Kingdom Home
Office regulations.
Isolation of E-SLAM HSCs
Suspensions of BM cells from adult JAK2V617F or WT mice
were isolated from the femurs, tibias, and hips and depleted of
red blood cells by a lysis step (BD PharmLyse). E-SLAM cells
were isolated as described previously [24] using CD45-FITC
[Clone 30-F11 BD Biosciences, San Jose, CA (BD)], EPCR-PE
(Clone RMEPCR1560, STEMCELL Technologies, Vancouver
(STEMCELL)], CD150-Pacific Blue or PE-Cy7 [Clone TC15-
12F12.2, both from Biolegend, San Diego, USA (Biolegend)], and
CD48-APC (Clone HM48-1, Biolegend). The cells were sorted
on a MoFlo (Beckman Coulter) using the following filter sets
[530/30 (for FITC), 580/30 (for PE), 630/40 (for APC), and
450/20 (for Pacific Blue)]. Cells were first sorted at a high rate
(10,000–15,000 cells/s) using an EPCR+CD482 gate that
captured approximately 0.5%–1% of all the viable cells and
were then resorted at a slower rate (1–200 cells/s) to improve the
efficiency of single-cell sorting. When low numbers of E-SLAM
HSCs were required, the single-cell deposition unit of the sorter
was used to place 1–10 of these cells into the wells of round-
bottom 96-well plates, each well having been preloaded with
50 mL serum-free medium.
Bone Marrow Transplantation Assays
Donor cells (105 or 106 whole BM) were obtained 6–10 mo after
pIpC injection from JAK2V617F mice or WT littermate controls
(CD45.2). For purified HSC transplants, 10 E-SLAM HSCs were
sorted into 96-well plates as described previously [24]. For
transplantations of cells derived from 10-d cultures, 100–400 E-
SLAM HSCs were cultured in bulk and various doses transplant-
ed. For secondary transplants, whole BM was obtained and
,66106 cells containing a mixture of recipient, competitor, and
Hematopoietic Stem Cell Subversion by JAK2 V617F
PLOS Biology | www.plosbiology.org 11 June 2013 | Volume 11 | Issue 6 | e1001576
donor-derived cells were transplanted. All competitor BM cells
were obtained from WT C57BL/6J (CD45.1/CD45.2) mice, and
between 200,000 and 500,000 whole BM cells were transplanted
along with donor cell fractions. For all transplantation assays,
recipients were C57BL/6J (CD45.1) mice irradiated with a split
dose (26475 cGy) and all transplants were performed by standard
intravenous tail vein injection using a 29.5G insulin syringe.
Peripheral blood was collected and analyzed as described
previously [64].
In Vitro Cultures
E-SLAM HSCs were sorted and cultured in serum-free media
containing 300 ng/mL SCF and 20 ng/mL IL-11. For the
immunophenotyping studies, clones were individually stained
and assessed for the expression of Sca1, c-Kit, CD41, CD11b,
Ly6g, CD71, and a panel of lineage markers. For assessment of
apoptosis, cells were stained with 7-Aminoactinomycin D (7AAD,
Invitrogen) and Annexin V FITC (BD). See Methods S1 for clone
size calculations and antibody information.
Paired Daughter Cell Analyses
Single HSCs were isolated and cultured in individual wells of a
96-well plate. At 24 h wells were scored for the presence of a single
cell (i.e., any doublets were excluded). At 36 h, wells were again
scored for the presence of doublets and any wells with two or more
cells were excluded. At 42 h, wells were scored to identify cells that
had divided between 36 and 42 h. In order to ensure that all cells
were at least 2 h postdivision, these wells were harvested at 44 h,
and all contained doublets that had undergone their first division
between 36 and 42 h. Daughter cells were separated by harvesting
the contents of the entire well and distributing those contents
across four newly prepared wells pre-filled with 50 mL of media
containing the same amount of SCF and IL-11. Wells that
received both daughter cells were excluded from the downstream
analysis. Following an additional 8 d of culture (10 d in total),
clones were harvested and analyzed individually by flow cytom-
etry.
To assess whether or not an individual clone had differentiated,
the average fraction of KSL cells from the WT was used as a
benchmark. Each doublet in which the expression levels of both
colonies were above the average were scored as a ‘‘no
differentiation,’’ while cases with one above and one below were
considered to be associated with an asymmetrical fate outcome,
etc. While such an assignment for an individual split doublet
would be vulnerable to statistical noise due to the stochastic nature
of subsequent divisions, we would expect that the average over
many doublets would converge onto the true proportions.
Peripheral Blood Analysis
For all transplantation assays, peripheral blood samples were
collected from the tail vein of mice at 4, 8, and 16 wk after
transplantation and analyzed for repopulation levels as described
previously [64]. Antibodies used were CD45.1-PE (Clone A20,
Biolegend), CD45.2-FITC (Clone 104, BD), Ly6g-Pacific Blue
(Clone RB6-8C5, Biolegend), Mac1-APC (Clone M1/70, Biole-
gend), B220-APC (Clone RA3-6B2 eBiosciences, San Diego, CA),
and CD3e-Pacific Blue (Clone 500A2, BD).
Clone Size Calculations and Antibody Information for in
Vitro Cultures
At 10 d, clones were estimated to be small (50–5,000 cells),
medium (5,000–10,000 cells), or large (10,000 or more cells). No
clones had fewer than 50 cells. Ten-day clones were stained with
biotinylated lineage marker antibodies (hematopoietic progenitor
enrichment cocktail, STEMCELL), c-kit APC (BD), and Sca1-
Pacific Blue (Biolegend). To enumerate cells, a defined number of
fluorescent beads (Trucount Control Beads, BD) were added to
each well and each sample was back calculated to the proportion
of the total that were run through the cytometer. Small clones
were not able to be assessed individually by flow cytometry and
were pooled—in all such cases, the percentage of KSL cells was
greater than 90%. For the 14-d immunophenotyping studies, cells
were co-stained with CD71-FITC (BD), CD41-PE (BD), Ly6g-
Pacific Blue (Biolegend), and CD11b-APC (Biolegend). Flow
cytometry was performed on a Cyan ADP (Beckman Coulter) or
an LSRII Fortessa (BD) and all data were analyzed using Flowjo
(Treestar, USA).
Assessment of PV and MF Transformation
Blood counts of mice were routinely performed to monitor for
disease transformation. Mice were considered to have transformed
to PV when hemoglobin levels were greater than 200 g/l. Mice
were considered to have transformed to MF when they became
cytopenic and had a palpable spleen. Postmortem analysis
confirmed transformation by assessing spleen size and histology.
Details of each transformed mouse can be found in Table S1.
Colony Forming Assays
Bulk cultures of 100–400 E-SLAM HSCs were harvested and a
proportion of cells were used for colony-forming cell (CFC) assays.
Assays were performed in a methylcellulose-based medium
(M3434) (STEMCELL) as described by the manufacturer.
Statistical Analyses
For calculating stem cell frequency and obtaining Chi-squared
values, we used the web-based calculator at http://bioinf.wehi.
edu.au/software/elda/ [65]. The Fisher Exact test was used to
determine whether or not clones from paired daughters had
undergone an increased or decreased number of differentiation
divisions. For all other p values reported, a two-tailed unpaired
Student’s t-test (Microsoft Excel) was used.
Supporting Information
Figure S1 JAK2V617F E-SLAM HSCs do not enter the cell
cycle more quickly than WT HSCs and do not differ in numbers
of dead or dying cells in 10-d cultures. (A) A total of 429 E-SLAM
HSCs from mice 6–10 mo following pIpC injection (n=251 for
JAK2V617F, n=178 for wild type) were deposited individually into
96-well plates, visually confirmed to be single cells at 16 h, and
then wells were scored every 6–12 h for early time points and
once per day from day 5 onward. A cell was scored as having
undergone a first division when a second cell could be observed in
the well and a second division when a third cell could be seen. A
Lowess spline curve was generated in GraphPad Prism (version
4.03) using 248 values estimated based on the marked values in
the time course and is shown for each of the first and second
divisions of E-SLAM HSCs from each genotype. (B) Represen-
tative flow cytomtery plots for cultures of 100–400 E-SLAM
HSCs following 10 d of culture in SCF and Il-11. In both the
entire pool as well as in the stem/progenitor fraction (Kit+Sca+-
Lin2, KSL), no differences in 7AAD/Annexin V staining were
noted. (C) Individual E-SLAM HSCs were cultured and cell
counts were performed on day 2 to determine whether or not
they had undergone a division in three independent experiments.
No difference was observed between HSCs from wild type (blue
bar) and JAK2V617F (red bar) littermates. (D) The bar graph
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shows the results of cell homing assays that measured the number
of HSCs in the BM of recipient mice 36 h after transplantation.
No difference was observed in homing efficiency between HSCs
from wild type (blue bar) and JAK2V617F (red bar) littermates. (E)
The bar graph shows the frequency of E-SLAM HSCs measured
in the BM of a single mouse that had transformed to PV 12 mo
after pIpC injection. Unlike nontransformed JAK2V617F animals
that have reduced E-SLAM numbers, the number of E-SLAM
cells was not reduced, but instead appear to be increased
compared to an age-matched WT control. HSCs from wild type
(blue bar) and JAK2V617F (red bar) are shown.
(TIF)
Figure S2 Expansion of colonies derived from single HSCs over
the 10-d time course. Colonies derived from WT (yellow) and
JAK2V617F mutant cells (orange) show an approximate exponen-
tial increase in size over the 10-d time course. For colonies of less
than 50 cells, the total cell number was recorded exactly. Colonies
in excess of 50 cells were grouped into three broad categories of
small (ca. 300 cells), medium (ca. 2k cells), and large (ca. 10k cells).
The logarithmic scale highlights the near-geometric (exponential)
expansion of the colonies over the entire 10-d time course.
(TIF)
Figure S3 Direct comparison of WT and JAK2V617F mutant
colony size distributions. (A) Data points show the composition of
individual colonies derived from WT HSCs (grey) and JAK2V617F
mutant cells (yellow) after 10 d. (B) Comparison of the cumulative
clone size distribution of colonies derived from single HSCs from
WT and JAK2V617F mutants after 10 d. The data suggest that the
JAK2V617F mutant data are tilted toward differentiation.
(TIF)
Figure S4 Cell type composition of colonies derived from single
HSCs. Data points (yellow) show the composition of individual
colonies derived from (A) WT HSCs and (B) JAK2V617F mutant
HSCs after 10 d. The grey points are a representative cohort of
colonies obtained from the numerical simulation of the model with
parameters defined in the main text and Supporting Information.
Note that, in both cases, while the numerical simulation captures
of the overall shape of the distribution, the scatter of the
experimental data is somewhat larger than that predicted by the
model dynamics. For further discussion, see the main text and
Supporting Information.
(TIF)
Figure S5 Analysis of the degree of bias of JAK2 mutant HSCs
toward differentiation. Comparison of the colony growth (left)
and cumulative clone size distribution (right), disaggregated by
cell type, of the JAK2V617F mutant HSCs with the modeling
scheme with a bias of (A) 90% (delta = 0.4) and (B) 70%
(delta = 0.2) towards differentiation of the HSC compartment and
model parameters defined in the Supporting Information section.
Points show the results of experiment. (Error bars denote SEM.)
The line on the growth curve shows the model prediction with
the given parameters. The bars on the cumulative size distribution
show the expected range of statistical fluctuations as predicted by
the model dynamics. More precisely, the bars (color coded by cell
type) represent the standard deviation of the results of the nume-
rical simulation with multiple trials involving a cohort size of 125
colonies, consistent with that used for the experimental data.
(TIF)
Figure S6 Effect of aging on the colony size distribution. (A)
Comparison of the measured size distribution of colonies derived
from single HSCs in young (yellow) and old (grey) WT mice after
10 d. Note that, although the average size of the separate
compartments in old mice is smaller, the overall distribution is
similar in spread and correlation between different cell types. (B)
Fit of the measured clone size distribution of the different cell types
in colonies derived from single HSCs in WT mice at 10 d
postplating (points) with predictions of the model with the
parameters the same as that specified in Figure 5A, but with an
activation period 0.5 d longer. (Error bars denote SEM.)
(TIF)
Table S1 JAK2V617F animals progress to more severe disease.
Each of the mice that progressed to more severe disease is
indicated by a unique number (1–10) and its main blood
parameters are reported. Hct, hematocrit; Plt, platelets; Hb,
hemoglobin; WBCs, white blood cell count; ND, not done. Mice
numbered 1 through 6 are from the C57BL/6J background and
those numbered 7 through 10 are 129 Sv/C57BL/6J hybrids.
(DOCX)
Methods S1 Description of additional techniques including
Isolation of E-SLAM HSCs, Bone marrow transplantation,
peripheral blood analysis, clone size, calculations, and antibody
information for in vitro cultures, E-SLAM homing assay, and
paired daughter cell analyses.
(DOCX)
Model S1 Supplementary theory to explain the mathematical
model, its assumptions, and conclusions.
(PDF)
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